- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/16 - Anti-Parkinson drugs
Patent holdings for IPC class A61P 25/16
Total number of patents in this class: 5332
10-year publication summary
|
173
|
225
|
373
|
465
|
399
|
456
|
468
|
461
|
388
|
195
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7929 |
72 |
| Takeda Pharmaceutical Company Limited | 2711 |
59 |
| H. Lundbeck A/S | 1234 |
47 |
| Hoffmann-La Roche Inc. | 3405 |
46 |
| Janssen Pharmaceutica N.V. | 3399 |
36 |
| Sumitomo Pharma Co., Ltd. | 586 |
35 |
| The Regents of the University of California | 19868 |
33 |
| Taisho Pharmaceutical Co., Ltd. | 870 |
29 |
| Genentech, Inc. | 3975 |
28 |
| Sumitomo Dainippon Pharma Co., Ltd. | 216 |
27 |
| Bristol-myers Squibb Company | 4878 |
26 |
| Merck Sharp & Dohme LLC | 3749 |
25 |
| Novartis AG | 10867 |
24 |
| Pfizer Inc. | 3379 |
24 |
| Eisai R&D Management Co., Ltd. | 1238 |
24 |
| AstraZeneca AB | 2917 |
23 |
| BIAL - Portela & CA, S.A. | 224 |
23 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 823 |
23 |
| The Johns Hopkins University | 5659 |
22 |
| Osaka University | 3374 |
22 |
| Other owners | 4684 |